AZ, Daiichi Sankyo sign US Movantik deal
This article was originally published in Scrip
AstraZeneca is teaming up with Daiichi Sankyo, using the Japanese pharma's US-based sales teams and expertise in the primary care setting to commercialize its first-in-class mu-opioid receptor antagonist Movantik (naloxegol) in the US.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.
The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.